SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+11.27%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$629M
AUM Growth
+$629M
(+9.7%)
Cap. Flow
-$333K
Cap. Flow
% of AUM
-0.05%
Top 10 Holdings %
Top 10 Hldgs %
38.9%
Holding
144
New
36
Increased
32
Reduced
27
Closed
33
Top Buys
| 1 |
Gilead Sciences
GILD
|
$25.1M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$19.2M |
| 3 |
Amgen
AMGN
|
$18.5M |
| 4 |
BLUE
bluebird bio
BLUE
|
$11.4M |
| 5 |
GSK
GSK
|
$10.7M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
$28.5M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$14.3M |
| 3 |
Sarepta Therapeutics
SRPT
|
$13.7M |
| 4 |
SHPG
Shire pic
SHPG
|
$11.8M |
| 5 |
Amicus Therapeutics
FOLD
|
$10.3M |
Sector Composition
| 1 | Healthcare | 83.93% |
| 2 | Technology | 7.06% |
| 3 | Industrials | 1.82% |
| 4 | Consumer Discretionary | 1.62% |
| 5 | Financials | 1.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Merck
MRK
$210B
| $41.3M | 5.69% | 680,000 +100,000 | +17% | +$6.07M |
|
2
Viatris
VTRS
$12.3B
| $30.9M | 4.26% | 854,000 +280,000 | +49% | +$10.1M |
|
|
3
GSK
GSK
$79.9B
| $30.8M | 4.25% | 765,000 +265,000 | +53% | +$10.7M |
|
|
4
Gilead Sciences
GILD
$140B
| $25.1M | 3.47% | +355,000 | New | +$25.1M |
|
|
SHPG
5
DELISTED
Shire pic
SHPG
| $21.4M | 2.94% | 126,500 -70,000 | -36% | -$11.8M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $19.9M | 2.75% | 160,544 +78,544 | +96% | +$9.75M |
|
|
7
Alnylam Pharmaceuticals
ALNY
$58.5B
| $19.2M | 2.65% | +195,232 | New | +$19.2M |
|
|
8
Sarepta Therapeutics
SRPT
$1.78B
| $19.2M | 2.64% | 145,096 -103,901 | -42% | -$13.7M |
|
|
9
Amicus Therapeutics
FOLD
$2.34B
| $18.6M | 2.56% | 1,189,056 -656,648 | -36% | -$10.3M |
|
|
10
Amgen
AMGN
$155B
| $18.5M | 2.54% | +100,000 | New | +$18.5M |
|
11
Biogen
BIIB
$19.4B
| $14.5M | 2% | 50,000 -15,000 | -23% | -$4.35M |
|
12
Pfizer
PFE
$141B
| $14.1M | 1.95% | 390,000 -200,000 | -34% | -$7.26M |
|
13
Clearside Biomedical
CLSD
$28.9M
| $11.4M | 1.58% | 1,068,720 +38,720 | +4% | +$414K |
|
|
BLUE
14
DELISTED
bluebird bio
BLUE
| $11.4M | 1.57% | +72,483 | New | +$11.4M |
|
|
AGN
15
DELISTED
Allergan plc
AGN
| $10M | 1.38% | 60,000 | – | – |
|
|
CLLS
16
Cellectis
CLLS
$258M
| $9.96M | 1.37% | 351,874 +12,507 | +4% | +$354K |
|
17
Travere Therapeutics
TVTX
$1.56B
| $9.63M | 1.33% | 353,072 +133,072 | +60% | +$3.63M |
|
|
ARQL
18
DELISTED
Arqule Inc
ARQL
| $8.28M | 1.14% | 1,497,683 -766,453 | -34% | -$4.24M |
|
|
NMTR
19
DELISTED
9 Meters Biopharma, Inc. Common Stock
NMTR
| $7.84M | 1.08% | 980,502 | – | – |
|
20
Viking Therapeutics
VKTX
$3.04B
| $7.43M | 1.02% | 782,424 -809,992 | -51% | -$7.69M |
|
21
Microsoft
MSFT
$3.77T
| $7.34M | 1.01% | 74,435 +7,585 | +11% | +$748K |
|
|
IMMU
22
DELISTED
Immunomedics Inc
IMMU
| $7.26M | 1% | 306,655 -173,345 | -36% | -$4.1M |
|
|
MLNX
23
DELISTED
Mellanox Technologies, Ltd.
MLNX
| $7.25M | 1% | 85,954 -14,325 | -14% | -$1.21M |
|
24
Minerva Neurosciences
NERV
$16.5M
| $6.77M | 0.93% | 820,120 +45,120 | +6% | +$372K |
|
25
Aldeyra Therapeutics
ALDX
$351M
| $6.73M | 0.93% | 846,935 -162,196 | -16% | -$1.29M |
|